title: Effect of ciclosporin on serum lipids and modification with LSL 90202, a lysine salt of eicosapentaenoic acid.
abstract: Ciclosporin (CS-A) has recently been considered a separate risk factor for the development of hyperlipidemia in transplant patients. In the present work, the effect of chronic CS-A administration on serum lipids and its modification using dietary supplementation with LSL 90202, a lysine salt of eicosapentaenoic acid, was studied. Thirty-one male Wistar rats were divided into four groups, receiving (1) 20 mg/kg CS-A in olive oil (CS-A group; n = 8); (2) isovolumetric olive oil (olive oil groups; n = 8); (3) 20 mg/kg CS-A in olive oil plus 20 mg/kg LSL 90202 (CS-A + LSL 20 group;) and (4) 20 mg/kg CS-A in olive oil plus 40 mg/kg LSL 90202 (CS-A+LSL 40 group; n = 8). Both, CS-A and LSL 90202 were given by daily gavage. On day 28, CS-A whole-blood levels and serum levels of total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol fractions (HDL, HDL-2, HDL-3, non-HDL), and malondialdehyde were measured. On day 28, the rats given CS-A showed significantly higher cholesterol, triglyceride, and non-HDL cholesterol serum levels than rats given olive oil. Rats given CS-A and LSL 90202 (20 mg/kg) showed significantly lower triglyceride serum levels than rats given CS-A only. Rats given CS-A and LSL 90202 (40 mg/kg) showed significantly lower triglyceride, total cholesterol, and non-HDL cholesterol serum levels than rats given CS-A only. There were no differences in HDL, HDL-2, and HDL-3 cholesterol serum levels between the groups. The CS-A whole-blood levels were not different between groups of animals given CS-A.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Serveis de Nefrología, Hospital de Bellvitge, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Torras
authors.forename: I
authors.initials: I
authors.lastname: Herrero
authors.forename: A
authors.initials: A
authors.lastname: Castells
authors.forename: J M
authors.initials: JM
authors.lastname: Galceran
authors.forename: C
authors.initials: C
authors.lastname: Fiol
authors.forename: D
authors.initials: D
authors.lastname: Seron
authors.forename: I
authors.initials: I
authors.lastname: Sabate
authors.forename: J
authors.initials: J
authors.lastname: Alsina
authors.forename: J M
authors.initials: JM
authors.lastname: Grinyo
mesh_terms: D000818:Animals; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000494:pharmacology*; D004347:Drug Interactions; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D000069463:Olive Oil; D010938:Plant Oils / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; C093633:LSL 90202; D008055:Lipids; D000069463:Olive Oil; D010938:Plant Oils; D014280:Triglycerides; D008315:Malondialdehyde; D016572:Cyclosporine; D002784:Cholesterol; D015118:Eicosapentaenoic Acid